Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

SANOFI_Presentation_EN

1,163 views

Published on

  • Be the first to comment

SANOFI_Presentation_EN

  1. 1. CORPORATE PRESENTATION 2011 1 Corporate Presentation SANOFIA global healthcare leader, focused on patients’ needs
  2. 2. A global healthcare leader, focused on patients’ needs 2 world’s largest pharmaceutical groups 1 employees in 110,000€30.43.7% (1) growth in net sales for 2010 billion (1) a reported basis countries100 CORPORATE PRESENTATION 2011 of the Source : 20F Form 2010, employees estimation march 2011, annual review 2010
  3. 3. 1973 to 2008 2009 to 2011 300mergers and acquisitions Diversified Healthcare Leader 10 110,000Employees Health, Beauty, Nutrition Evolution 3CORPORATE PRESENTATION 2011 Acquired companies including Genzyme +61in-licensing agreements +2joint ventures Invested a total of ~ €23bnin external growth 23 Source: employees estimation march 2011, IR presentation September 6, 2011
  4. 4. History of Sanofi 4 Sanofi- Synthélabo 1999 Sanofi 1973 Synthélabo 1970 Sanofi- aventis 2004 Aventis 1999 Hoechst Marion Roussel 1997 Rhône- Poulenc Rorer 1990 Chinoin 1919 Sterlin g 1901 Midy 1718 Hoechst 1920 Marion 1950 Institut Pasteur 1887 Rorer 1910 Connaught 1922 Delalande 1924 Delagrange 1931 BMP Sunstone, Medley, Merial, Nepentes, Zentiva, Kendricks, Oenobiol, Chattem, Acambis, Symbion, Shantha Biotechnics 2008-2010 Roussel 1911 Genzyme 2011 CORPORATE PRESENTATION 2011
  5. 5. Our commitment 5 Sanofi is more than a pharmaceutical laboratory; We act with our partners to protect health, enhance life and respond to the potential healthcare needs of the 7 billion people around the world we are a diversified healthcare company CORPORATE PRESENTATION 2011
  6. 6. Our ambition 6 We demonstrate leadership both in business achievements and in the communities in which we operate We are a global healthcare leader, focused on patients’ needs We wish to be known for our ability to transform scientific innovations into therapeutic solutions for patients CORPORATE PRESENTATION 2011
  7. 7. Our global presence 7 (1) US + Canada + Porto Rico (2) Western Europe + Eastern Europe + Turkey (3) Australia + New Zealand Africa, Middle East €846 M €789 M Employees Sales Africa Europe (2) €11,609 M Employees Sales North America (1) €9,484 M +15,000 Sales Employees South America €2,735 M 9,000 Sales Employees Japan €2,225 M Employees Sales Asia, Pacific (3) €1,983 M €713 M Sales Asia Employees+4,500 55,000 +3,000 +15,000 Sales Middle East Sales Pacific CORPORATE PRESENTATION 2011 Source: Solid results in 2010, press release Febuary 9th 2011
  8. 8. Our strategy 8 INCREASE INNOVATION IN R&D SEIZE EXTERNAL GROWTH OPPORTUNITIES ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES 1 2 3 CORPORATE PRESENTATION 2011
  9. 9. Accelerate innovation for patients 9 1. INCREASE INNOVATION IN R&D Sanofi R&D A new R&D model to improve health worldwide and bring therapeutic solutions to patients: • Simplification • Openness • Partnerships • Biotechnologies Priorities Diabetes Fibrosis and tissue repair Immuno-inflammation Infectious diseases Rare diseases Oncology Ophthalmology Aging R&D Portfolio Q2 results 2011 molecules and vaccines 65 2012 - 2015 19 potential new launches* CORPORATE PRESENTATION 2011 Source: IR presentation September 6, 2011
  10. 10. Develop innovative health solutions 10 1. INCREASE INNOVATION IN R&D Dengue vaccine Note : LemtradaTM (alemtuzumab), AubagioTM (teriflunomide) and Lyxumia® (lixisenatide) are brand names for projects currently in development for which all necessary regulatory authorizations have not been attained. (1) Licensed by Zealand Pharma A/S, expected regulatory submission in EU Q4 2011 and US Q4 2012 (2) expected regulatory submission in MS in US and EU Q1 2012 (3) filed in the US in Q3 2011 and expected regulatory submission in EU Q1 2012) (1) CORPORATE PRESENTATION 2011 (2014) Oncology Diabetes Vaccines Multiple sclerosis Biosurgey renal Source: IR presentation September 6, 2011 (2) (3)
  11. 11. Strengthen our activities through external growth 11 2. SEIZE EXTERNAL GROWTH OPPORTUNITIES Generics Human vaccines Consumer healthcare Diabetes Rare diseases Innovative products Animal health CORPORATE PRESENTATION 2011 REGULUS acquisitions and partnerships In 2009 acquisitions and partnerships In 2010 33 37 Source : annual review 2009 and 2010
  12. 12. Growth platforms: 57% of sales in 2010 (1) 12 3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES Emerging markets Human vaccines Consumer healthcare Diabetes solutions Innovative products Animal health CORPORATE PRESENTATION 2011 Source: IR presentation September 6, 2011 (1) Including sales of merial
  13. 13. Emerging markets(1): a new world vision 13 Brazil China Russia +51.4% (2) +23.6% (2) +19.9%(2) Sales Split (%): Results #1 #3 #2 (1) The World less the United States, Canada, Western Europe, Japan, Australia and New Zealand. Organic growth in emerging markets: + 13.2% in 2010. (2) At constant exchange rates. (3) RoW: Japan, Australia, New Zealand, Canada CORPORATE PRESENTATION 2011 +16.3 %(2) 3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES 30.4 % 12.2 % 28.5 % 28.9 % U.S. RoW (3) Emerging Markets Western Europe local production sites support market access 38 employees 40,000 Nearly Source : annual review 2010, presentation of Q2 2011 Results, IR presentation September 6, 2011
  14. 14. Human vaccines: Sanofi Pasteur, a world leader 14 Dengue vaccine Clostridium difficile vaccine (1) Growth at constant exchange rates 3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES Leadership position in pediatrics, flu, meningitis, travel & endemics Broad Product Offering Sales Split 2011e Flu Polio / Pertussis / Hib Boosters Other 6% 12% 11% 27% 13% 31% Meningitis / PneumoTravel / Endemics Today Tomorrow €3.8 bn +4.8% (1) consolidated sales in 2010 doses of seasonal influenza vaccine distributed worldwide 198,000,000 In 2010 12.5 % Vaccines for 20 infectious diseases CORPORATE PRESENTATION 2011 of Sanofi sales Source : annual rewiew 2010, presentation General meeting 2011 May 6, 2011, IR presentation September 6, 2011
  15. 15. Consumer healthcare: diversification and strong growth 15 Keys legacy brands In March 2011 Launch of Allegra® over the counter in the US €2,2 (1) Includes Chattem sales since 10 February 2010 +6.9% in 2010 on a constant structure basis ant at constant exchange rates 3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES bn 2010 Sales: +45.7 %(1) Sanofi has become a global player (2) #1in Latin America, in Australia #3 in Russia, in Central & Eastern Europe Scaling up in China and Asia Among top 10 in U.S (3) CORPORATE PRESENTATION 2011 (2) Nicolas Hall, OTC Yearbook, 2011, DBG 2011 (2011 Sales) (3) Including Allegra® OTC sales in 2011, internal estimates Source : annual rewiew 2010, IR presentation September 6, 2011
  16. 16. Diabetes solutions 16 Lantus® Amaryl® Apidra® BGStar® and iBGStar® BGStar® and iBGStar® Integrate BGM and Lantus® dosing device Lyxumia® (lixisenatide) Type 2 diabetes Lantus® in 2010 120,000,000Lantus® and SoloSTAR® pens sold insulin brand name worldwide +9.2%(1) 14.1% of Sanofi sales #1 #1 €3.5 bn diabetes treatment with sales of Today Tomorrow €4,3 bn CORPORATE PRESENTATION 2011 3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES (1) Growth at constant exchange rates Source : annual rewiew 2010, presentation General meeting 2011 May 6, 2011, IR presentation September 6, 2011
  17. 17. Innovative products: bringing new hope 17 Kynamro™ (mipomersen) hoFH(1) and Severe heFH(2) Visamerin® Mulsevo® (semuloparin) VTE(3) prevention in chemo-treated patients Aubagio™ (Teriflunomide) RMS(4) Zaltrap™ (Aflibercept) 2L-mCRC(5) Lyxumia® (lixisenatide) Type 2 diabetes Lemtrada™ (alemtuzumab) RMS (1) Homozygous Familial Hypercholesterolemia (2) Heterozygous Familial Hypercholesterolemia (3) Venous Thrombo Embolism (4) Relapsing forms of Multiple Sceloris (5) Metastatic Colorectal Cancer CORPORATE PRESENTATION 2011 3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES Source : IR presentation September 6, 2011
  18. 18. Animal health: Merial 18 More than €2.6 bn employees worldwide 150countries production sites 16 in sales in 2010, +2.6%(1) 5,700 With its range of vaccines and products to treat parasites, infection, inflammation and ulcers, Merial improves the health, well-being and performance of a large variety of animals. (1) Growth at constant exchange rates Present in more than CORPORATE PRESENTATION 2011 3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES Source : annual rewiew 2010
  19. 19. Genzyme, a Sanofi company 19CORPORATE PRESENTATION 2011 3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES TodayGlobal leader in rare genetic diseases Established, long-term partnerships - KOLs, - Patient groups, - Health authorities Technical expertise across broad range of technology platforms Tomorrow Personalized Genetic Health Multiple Sclerosis (1) (1) LemtradaTM (alemtuzumab), AubagioTM (teriflunomide) are brand names for projects currently in development for which all necessary regulatory authorizations have not been attained. 70 40 sites in more than in sales in 2010 countries $1,571m personalized Genetic Health Source : annual rewiew 2010, IR presentation September 6, 2011
  20. 20. Corporate social responsibility 20 We are a healthcare company with deep moral commitments Acting ethically and responsibly is part of our DNA Giving aid, both in emergencies and on a daily basis, means going beyond our immediate obligations to protect and serve as many human beings as possible. CORPORATE PRESENTATION 2011
  21. 21. Ensuring access to healthcare 21 CORPORATE SOCIAL RESPONSIBILITY To ensure that the human right to health becomes a reality, Sanofi develops programs to improve access to medicines for people in developing countries 7 disease areas for Access to Medicines Malaria Tuberculosis Sleeping sickness Leishmaniasis Epilepsy Mental health Vaccines Approach Information and education, Medicines adapted to patients needs, Tiered pricing policy R&D program for therapeutic innovation CORPORATE PRESENTATION 2011
  22. 22. 22 CORPORATE SOCIAL RESPONSIBILITY Respond Support Encourage Donations in 2010: boxes of medicines and vaccine doses to treat underprivileged people in 43countriesemployee involvement development aid to humanitarian emergencies 974,457 509,218 CORPORATE PRESENTATION 2011 Source : annual rewiew 2010
  23. 23. 23 CORPORATE SOCIAL RESPONSIBILITY HAITI Bringing access to healthcare to the population after the earthquake FRANCE Improving medical care for the homeless ALGERIA Diagnosing and socially rehabilitating children with mental difficulties BRESIL Fighting leishmaniasis BURUNDI Training healthcare professionals. NEPAL Fighting infant and maternal mortality INDIA Combining access to healthcare and mutual health support PHILIPPINES Caring for street childrenTOGO Fighting Buruli ulcer TANZANIA Fighting childhood cancer Our dedication to healthcare for all: a few examples from around the world PÉROU Enhancing access to healthcare in slums PERU CORPORATE PRESENTATION 2011 Source : annual rewiew 2010,
  24. 24. Embracing environmental responsibility 24 CORPORATE SOCIAL RESPONSIBILITY Safeguarding the environment is one of Sanofi’s responsibilities as a global healthcare partner. The connection between environmental hazards and impact on health has been clearly established. Because we are focused on patients’ needs, reducing environmental risk is a natural part of our CSR practices Carbon footprint and energy consumption One of Sanofi’s priority to reduce its environmental impact is to control our carbon footprint and reduce our energy consumption. Since 2005, for every unit produced, the Group has decreased direct CO2 emissions by 8 % and indirect emissions by 17 %. CORPORATE PRESENTATION 2011 Source : annual rewiew 2010
  25. 25. Recommendation 25PRÉSENTATION INSTITUTIONNELLE 2011 This corporate presentation is available for all employees in the Sanofi Group. It may be used internally or externally for presentations of the Group, either in whole or in part, as needed. The information is taken from Information meetings, annual results 2010 and from press releases. Further information is available on www.sanofi.com Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Photography credits : Urbanhearts/Fotolia - Gil Corre - Krzysztof Dydynski/lonely Planet Images/Getty Images - Imagesource V/Fotolia - Gil Corre - Eric Larrayadieu/Interlinks Image - Merial - Julien Chraibi - Gil Corre - Gil Corre (Haïti, Brésil, France, Tanzanie) - samusocial International (Pérou) - Santé Sud (Algérie) - Jean-Jacques Bernard (Togo) - Chirurgie solidaire (Burundi) - InterAide (Inde) - Stéphane Lehr (Népal) - Virlanie (Philippines) – Getty Images/MIXA
  26. 26. 26 Further informations: www.sanofi.com SANOFI Headquarters 174, avenue de France 75013 Paris, France Tel. +33 (0)1 53 77 40 00 CORPORATE PRESENTATION 2011

×